Conflict of interest statement: There are no conflicts of interest.177. South Asian J Cancer. 2018 Apr-Jun;7(2):142-145. doi: 10.4103/sajc.sajc_122_18.Practical consensus recommendations on duration of adjuvant hormonal therapy inbreast cancer.Gupta S(1), Singh M(2), Vora A(3), Babu G(4), Walia M(5), Nautial V(6), SahaR(5), Smruti BK(7), Sharma JB(8), Koul R(9), Parikh PM(10), Aggarwal S(11).Author information: (1)Department of Medical Oncology, Tata Memorial Center, Mumbai, Maharashtra,India.(2)Department of Medical Oncology, Mahaveer Cancer Sansthan, Patna, Bihar, India.(3)Department of Medical Oncology, Hope Clinic, New Delhi, India.(4)Department of Medical Oncology, KMIO, Bengaluru, Karnataka, India.(5)Department of Medical Oncology, Max Hospital, New Delhi, India.(6)Department of Medical Oncology, Jolly Grant Himalayan Institute, Dehradoon,Uttarakhand, India.(7)Department of Medical Oncology, Bombay Hospital, Mumbai, Maharashtra, India.(8)Department of Medical Oncology, Action Balajee Cancer Hospital, New Delhi,India.(9)Department of Surgical Oncology, Sir Ganga Ram Hospital, New Delhi, India.(10)Department of Oncology, Shalby Cancer and Research Institute, Mumbai,Maharashtra, India.(11)Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India.Optimization of adjuvant systemic therapy in women with early-stage hormonereceptor-positive breast cancer includes the consideration of chemotherapy andduration of hormone therapy. Adjuvant hormonal therapy significantly improveslong-term survival of breast cancer patients with hormone receptor-positivedisease. Despite the proven clinical efficacy of tamoxifen and aromataseinhibitors, many breast cancer survivors either fail to take the correct dosageat the prescribed frequency (adherence) or discontinue therapy (persistence).Expert oncologist discussed on the duration of adjuvant hormonal therapy forimprovement of OS and quality of life of breast cancer patients by providingreduction in recurrence and mortality. This expert group used data from publishedliterature, practical experience and opinion of a large group of academiconcologists to arrive at this practical consensus recommendations for the benefitof community oncologists.DOI: 10.4103/sajc.sajc_122_18 PMCID: PMC5909293PMID: 29721482 